The glutamate-rich protein (GLURP) of P. falciparum is the target of cytophilic antibodies
which are significantly associated with protection against clinical malaria. A phase 1 clinical
trial was conducted in healthy adult volunteers with the long synthetic peptide (LSP)
GLURP85–213 combined with either Aluminum Hydroxide (Alum, 18 volunteers) or
Montanide ISA 720 (ISA, 18 volunteers) as adjuvants. Immunizations with 10, 30 or 100μg
GLURP85–213 were administered subcutaneously at days 0, 30, and 120. Adverse ...
